SeaBeLife, a Roscoff, France-based biotech company developing drug candidates intended to block cell necrosis, raised €1.2M in additional Seed funding.
The round, which brough the total amount to €1.6M, was led by XLife fund and business angel networks including Breizh Angels, Angels Santé, WeLike and BAdGE.
The company intends to use the funds to finance the regulatory development of its drug candidates, notably for acute liver disease and eye disorders, and leverage its patented technology that targets two regulated cell death pathways. The funding also enables team expansion, with the hiring of several specialists to set up clinical trials.
Led by CEO Morgane Rousselot, SeaBeLife is a biotechnology company that specializes in the development of drug candidates that block cellular necrosis in order to protect or regenerate organs affected by severe pathologies – for which there are no alternative, effective treatments. It mainly focuses on acute liver disease (acute hepatitis and fulminant hepatitis), including paracetamol poisoning, but is also pursuing research into age-related macular degeneration (AMD), Parkinson’s disease and other neurodegenerative diseases (including Alzheimer’s). SeaBeLife’s platform technology centers around a portfolio of more than 150 biologically active relevant molecules, which have the characteristic of inhibiting two forms of regulated and programmed cell death – necroptosis and ferroptosis – in pathological conditions.
FinSMEs
26/09/2023